FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 10/594413

APPLICANT
PALERMO ET AL.
FILING DATE

Group

			U.S. F	PATEN	T DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE
	AA							
	AB							7 7 112 114
	AC							
	AD							
-	AE							
	AF							
	AG							
	АН							
	AI							
	AJ						 	
	AK							
	AL							
	1	· · · · · · · · · · · · · · · · · · ·	EODEIG	N DAT	ENT DOCUMENT	· ·		
							SUBCLASS TRANSLATION	
		DOCUMENT NUMBER	DATE		OFFICE	CLASS	SUBCLASS	YES NO
	AM	WO 2004/005248	1/15/04	WIPO				
000000000000000000000000000000000000000		WO 01/90070	11/29/01	- WIDG	200000000000000000000000000000000000000	***************************************	***************************************	
	AO							
	AP							
	AQ							
		OTHER DOC	UMENTS ((Includin	g Author, Title, Date,	Pertinent pages, E	itc.)	
	Arnt et al., "Synthetic SMAC/Diablo peptides enhance the effects of chemotherapeutic agents by							
	AR binding XIAP and CIAP1 in situ," Journal of Biological Chemistry, Vol. 277(46), pp. 44236-44243 (2002)							
Kipp et al "Molecular targeting of inhibitor of apoptosis based on small molecule mimics of n AS binding partners," Biochemistry, Vol. 41(23), pp. 7344-7349 (2002)								s of natural
	AS binding partners," Biochemistry, Vol. 41(23), pp. 7344-7349 (2002)							
000000000000000000000000000000000000000	——————————————————————————————————————	Wu et al., "Structural	analysis of a	function	onal DIAP1 fragme	nt bound to grin	n and hid pep	tides,"
000000000000000000000000000000000000000	AT	Wu et al., "Structural Molecular Cell, Vol. 8	analysis of a (1), pp. 95-1	functio	onal DIAP1 fragme 01)	nt bound to grin	n and hid pep	etides,"

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

EXAMINER

/Ronald Niebauer/

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 33727-US-PCT APPLICATION NO.

10/594413

Sheet 2 of 2

01/24/2011

APPLICANT PALERMO ET AL. FILING DATE

18 Rec'd PCT/PTO 26 SEP 2006

U.S. PATENT DOCUMENTS EXAMINER DOCUMENT NUMBER DATE NAME CLASS **SUBCLASS FILING DATE** INITIAL BA BB BC BD ΒE BF BG BH ВΙ BJ BK BL **FOREIGN PATENT DOCUMENTS** TRANSLATION YES NO **DOCUMENT NUMBER** DATE **OFFICE CLASS** SUBCLASS BM BN BO BP BQ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Deal et al., "Conformationally constrained tachykinin analogues: potent and highly selective neurokinin NK-z-receptor antagonists," Journal of Medicinal Chemistry, Vol. 35(22), pp. 4195-4204 BR (1992)BS BT

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

DATE CONSIDERED